Krystal Biotech Inc
KRYS
NASDAQ
Biotechnology
$332.27
USD
+3.93 (+1.20%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $9.71B
Volume 167.9K
Revenue
$440.48M
TTM
+22.6%
YoY
Gross Margin
95%
TTM
+1.4%
YoY
Net Income
$241.46M
TTM
+64.6%
YoY
Operating Cash Flow
$272.34M
TTM
+39.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 96.0 | 97.8 | 107.1 | 116.4 | 119.2 |
YoY Growth | +36.6% | +16.6% | +17.5% | +31.9% | +24.1% |
Cost of Revenue | 7.2 | 4.3 | 6.6 | 6.3 | 6.4 |
Gross Profit | 88.9 | 93.5 | 100.5 | 110.0 | 112.8 |
Selling, General & Administrative | 35.1 | 37.6 | 41.4 | 41.0 | 39.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 49.5 | 52.2 | 56.2 | 56.3 | 54.4 |
Operating Income | 39.4 | 41.4 | 44.3 | 53.7 | 58.4 |
EBITDA | 40.7 | 42.8 | 45.8 | 55.2 | 59.8 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 7.4 | 6.6 | 6.9 | 7.8 | 7.7 |
Income Before Income Taxes | 46.8 | 48.0 | 51.1 | 61.4 | 66.1 |
Income Taxes | 8.4 | -31.4 | -0.3 | 5.5 | 11.3 |
Net Income | 38.3 | 79.4 | 51.4 | 55.9 | 54.8 |
Consolidated Net Income / Loss | 38.3 | 79.4 | 51.4 | 55.9 | 54.8 |
Net Income Attributable to Common Shareholders | 38.3 | 79.4 | 51.4 | 55.9 | 54.8 |
Basic EPS | $1.33 | $2.74 | $1.77 | $1.91 | $1.85 |
Diluted EPS | $1.29 | $2.66 | $1.69 | $1.83 | $1.79 |
Basic Shares Outstanding | 28.9M | 29.0M | 29.1M | 29.3M | 29.5M |
Diluted Shares Outstanding | 29.7M | 29.8M | 30.4M | 30.5M | 30.7M |